Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: Treatment efficacy and toxicity in U87 and C6 intracranial gliomas

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3282-3292

  Moroz, Maxim A ^a   Huang, Ruimin ^a   Kochetkov, Tatiana ^a   Shi, Weiji ^a   Thaler, Howard ^a   De Stanchina, Elisa ^a   Gamez, Idoia ^b   Ryan, Robert P ^b   Blasberg, Ronald G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Celtic Pharmaceutical Development Services America Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; DEXAMETHASONE; MESSENGER RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; XERECEPT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CORTICOTROPIN-RELEASING HORMONE; DACARBAZINE; DEXAMETHASONE; GLIOMA; HUMANS; MALE; MICE; MICE, NUDE; RATS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956042307     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3203     Document Type: Article

References (41)

1. Tjuvajev J, Uehara H, Desai R, Beattie B, Matei C, Zhou Y, et al. Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res 1996;56:1352-60. (Pubitemid 26080979)
2. Villalona-Calero MA, Eckardt J, Burris H, Kraynak M, Fields-Jones S, Bazan C, et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol 1998;9:71-7. (Pubitemid 28125767)
3. Bale TL, Giordano FJ, Vale WW. A new role for corticotropin-releasing factor receptor-2: suppression of vascularization. Trends Cardiovasc Med 2003;13:68-71. (Pubitemid 36175530)
4. Moliterno JA, Henry E, Pannullo SC. Corticorelin acetate injections for the treatment of peritumoral brain edema. Expert Opin Investig Drugs 2009;18:1413-9.
5. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5:610-20.
6. Moustakas A, Kreisl TN. New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. OncoTargets Ther 2010;3:27-38.
7. Pavlidis ET, Ballas KD, Symeonidis NG, Psarras K, Koliakos G, Kouzi-Koliakos K, et al. The effect of bevacizumab on colon anastomotic healing in rats. Int J Colorectal Dis 2010;25:1465-73.
8. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:4589-99.
9. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-6.
10. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9:444.
11. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394-7. (Pubitemid 12243637)
12. Brown JK HA. Toxic encephalopathy and acute brain-swelling in children. Dev Med Child Neurol 1975;17:659-79.
13. Taylor AL, Fishman LM. Corticotropin-releasing hormone. N Engl J Med 1988;319:213-22.
14. Kiang JG, Poree L, Wei ET. Anti-inflammatory activity of corticotropin releasing factor: II. Mechanisms of action. Proc West Pharmacol Soc 1987;30:63-5. (Pubitemid 17132687)
15. Serda SM, Wei ET. Epinephrine-induced pulmonary oedema in rats is inhibited by corticotropin-releasing factor. Pharmacol Res 1992;26:85-91.
16. Wei ET, Kiang JG, Tian JQ. Anti-inflammatory activity of corticotropin releasing factor: I. Efficacy studies. Proc West Pharmacol Soc 1987;30:59-62.
17. Wei ET, Thomas HA. Anti-inflammatory peptide agonists. Annu Rev Pharmacol Toxicol 1993;33:91-108. (Pubitemid 23116002)
18. Thomas HA, Ling N, Wei ET. CRF and related peptides as anti-inflammatory agonists. Ann N Y Acad Sci 1993;697:219-28. (Pubitemid 24028966)
19. Wei ET, Gao GC. Corticotropin-releasing factor: an inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury. Regul Pept 1991;33:93-104.
20. Reubi JC, Waser B, Vale W, Rivier J. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 2003;88:3312-20. (Pubitemid 36877510)
21. Wei ET, Gao GC, Thomas HA. Peripheral anti-inflammatory actions of corticotropin-releasing factor. Ciba Found Symp 1993;172:258-68; discussion 268-76.
22. Tjuvajev J, Kolesnikov Y, Joshi R, Sherinski J, Koutcher L, Zhou Y, et al. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo 1998;12:1-10. (Pubitemid 28177273)
23. Chrousos GP, Schulte HM, Oldfield EH, Gold PW, Cutler GB Jr, Loriaux DL. The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med 1984;310:622-6. (Pubitemid 14151190)
24. Recht LD, Mechtler L, Phuphanich S, Hormigo A, Hines V, Milsted E, et al. A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patience with primary or metastatic brain tumors and peritumoral edema. J Clin Oncol 2009;27:abstr 2078.
25. Shapiro WR, Mechtler L, Cher L, Wheeler H, Hines V, Milsted E, et al. A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primary malignant glioma who require increased dexamethasone to control symptoms of peritumoral brain edema. J Clin Oncol 2009;27:abstr 2080.
26. Mechtler L WE, Hormigo A, Pannullo S, Hines V, Milsted R, O'Connor PO, et al. A long-term open-label extension study examining the steroid-sparing effects of corticorelin acetate in patients with cerebral tumors. J Clin Oncol 2009;27:abstr 2079.
27. Leff RS, Thompson JM, Daly MB, Johnson DB, Harden EA, Mercier RJ, et al. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 1988;62:32-5.
28. Treadwell BL, Sever ED, Savage O, Copeman WS. Side-effects of long-term treatment with corticosteroids and corticotrophin. Lancet 1964;1:1121-3.
29. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 1995;55:1902-10.
30. Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophine-releasing factor, Xerecept. Published by Neurobiological Technologies. Drugs R&D 2004;5:218-9.
31. Moroz E, Carlin S, Dyomina K, Burke S, Thaler HT, Blasberg R, et al. Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One 2009;4:e5077.
32. Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging 2004;31:740-51. (Pubitemid 38647915)
33. Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T, et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 2004;64:6101-8. (Pubitemid 39129410)
34. Ngamwongsatit P, Banada PP, Panbangred W, Bhunia AK. WST-1- based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J Microbiol Method 2008;73:211-5.
35. Ciusani E, Balzarotti M, Calatozzolo C, de Grazia U, Boiardi A, Salmaggi A, et al. Valproic acid increases the in vitro effects of nitrosoureas on human glioma cell lines. Oncol Res 2007;16:453-63.
36. Tannock I, Guttman P. Misonidazole increases the toxicity of BCNU for hypoxic cells. Int J Radiat Oncol Biol Phys 1982;8:663-6. (Pubitemid 12090604)
37. Schoeffter P, Feuerbach D, Bobirnac I, Gazi L, Longato R. Functional, endogenously expressed corticotropin-releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells. Fundam Clin Pharmacol 1999;13:484-9. (Pubitemid 32250273)
38. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, et al. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 2002;143:807-13. (Pubitemid 34164029)
39. Carlson KW, Nawy SS, Wei ET, Sadee W, Filov VA, Rezsova VV, et al. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res 2001;21:1173-9.
40. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, et al. Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 2007;264:44-9. (Pubitemid 46097300)
41. CelticPharma. Celtic Pharma announces results of a phase III program evaluating XERECEPT® in patients with primary and metastatic brain tumors [press release]. Hamilton, Bermuda: CelticPharma; 2010.